AFB/TB - MDR (Multi Drug Resistance) Detection (INH and Rif) - HAINS Genotyping

This test is typically ordered if a patient diagnosed with tuberculosis is not responding as expected to standard treatment, or if drug resistance is suspected.

This test measures the presence of specific genetic mutations in the TB bacteria that are known to confer resistance to isoniazid and rifampicin.

The frequency of this test is determined by the healthcare provider based on the patient's condition and response to treatment.

A normal result would show no genetic mutations, suggesting that the TB bacteria should be sensitive to isoniazid and rifampicin. However, test results should always be interpreted in the context of other diagnostic information.

As with any medical test, it's important to provide an accurate sample for analysis. Follow your healthcare provider's instructions for sample collection.

The test results can be affected by improper sample collection, laboratory error, or the presence of a less common resistance-causing mutation not detected by this test.

Abnormal results should be discussed with an infectious disease specialist or a pulmonologist, who can guide further management.

Current anti-tuberculosis medications can influence the test results. Inform your healthcare provider of any medications you are currently taking.

Yes, this test can be performed on pregnant women suspected of having tuberculosis.

The risks associated with this test are minimal and are mostly related to the sample collection process. If tissue or fluid samples are needed, the procedures to collect these may carry additional risks.

The AFB/TB - MDR Detection - HAIN Genotyping test is a reliable tool for detecting resistance to isoniazid and rifampicin. However, the accuracy of the results depends on correct sample collection and laboratory procedures.

This test can indicate resistance to isoniazid and rifampicin, two of the main first-line anti-tuberculosis drugs. If resistance is detected, it may suggest multi-drug resistant TB, though further tests may be necessary to confirm this diagnosis.

This test is generally not used to monitor treatment effectiveness but rather to guide the choice of drugs to use for treatment.

The AFB/TB - MDR Detection - HAIN Genotyping test plays a crucial role in managing tuberculosis. By detecting resistance to first-line anti-tuberculosis drugs, healthcare providers can create tailored treatment plans to increase the likelihood of a successful outcome. Be sure to follow your healthcare provider's instructions for sample collection to ensure accurate results. Your health is important, so don't hesitate to ask your healthcare provider any questions you may have regarding this test.